Latest Breaking News On - Kirti sharma - Page 1 : comparemela.com

New preclinical data on novel E3 pairing and structural mechanisms for KT-333, a First-in-Class STAT3 degrader, presented in AACR’s late-breaking poster session Nello Mainolfi, Founder, President and CEO of Kymera, invited as a featured speaker in AACR’s Major Symposium to discuss drug discovery and clinical translation strategies for STAT3 and MDM2 degrader programs KT-333 and KT-253 Phase 1 dose escalation studies ongoing with additional data expected in 2024 WATERTOWN, Mass., April 08, 2024 (

United statesSan diegoJustine koenigsbergGen degradersKirti sharmaNello mainolfiAmerican society of hematologyKymera therapeutics incResource libraryAmerican association for cancer researchExchange commissionMajor symposiumAmerican societyAnnual meetingAmerican associationCancer research